Trial Profile
Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients with Type 2 Diabetes Treated with Metformin Alone or in Combination with Sulphonylurea
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Insulin detemir
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Amylin Pharmaceuticals; AstraZeneca
- 01 Apr 2018 Results of pooled post hoc analysis of this and other ten trials assessing the relationship of heart rate changes with baseline heart rate and identifying patient characteristics associated with changes in heart rate in the Exenatide QW development program published in the Diabetes Therapy
- 18 Sep 2014 Results of a pooled analysis of trials NCT00641056, NCT01003184, and NCT00935532 were presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 12 Jul 2014 This trial has been completed in Ireland and recruiting in United Kingdom as reported by European Clinical Trials Database record.